Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Volgraf

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cell Reports|January 16, 2020
GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease ModelsJesse E Hanson, Keran Ma, Justin Elstrott, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous systemAllen A Thomas, Kevin W Hunt, Matthew Volgraf, et al.
Journal of Medicinal Chemistry|March 30, 2018
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular ModelingHuifen Chen, Matthew Volgraf, Steven Do, et al.
Journal of Medicinal Chemistry|February 28, 2016
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based DesignMatthew Volgraf, Benjamin D Sellers, Yu Jiang, et al.
Journal of Medicinal Chemistry|March 22, 2021
Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron MicroscopyJack A Terrett, Huifen Chen, Daniel G Shore, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
The Journal of Experimental Medicine|February 23, 2021
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatmentAlessia Balestrini, Victory Joseph, Michelle Dourado, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cell Reports|January 16, 2020
GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease ModelsJesse E Hanson, Keran Ma, Justin Elstrott, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous systemAllen A Thomas, Kevin W Hunt, Matthew Volgraf, et al.
Journal of Medicinal Chemistry|March 30, 2018
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular ModelingHuifen Chen, Matthew Volgraf, Steven Do, et al.
Journal of Medicinal Chemistry|February 28, 2016
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based DesignMatthew Volgraf, Benjamin D Sellers, Yu Jiang, et al.
Journal of Medicinal Chemistry|March 22, 2021
Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron MicroscopyJack A Terrett, Huifen Chen, Daniel G Shore, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
The Journal of Experimental Medicine|February 23, 2021
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatmentAlessia Balestrini, Victory Joseph, Michelle Dourado, et al.
Pageof 3